(Q36827827)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

review article

1 reference

title

Nonalcoholic fatty liver disease: from pathogenesis to patient care (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

1 reference

1 reference

metabolic dysfunction–associated steatotic liver disease

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Gabriel Perlemuter

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Amélie Bigorgne

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Sylvie Naveau

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

1 reference

1 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Endocrinology and Metabolism

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

458-469

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

Nonalcoholic fatty liver disease

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Nonalcoholic fatty liver disease: an agenda for clinical research

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Leptin and liver fibrosis: A matter of fat

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Acute leptin deficiency, leptin resistance, and the physiologic response to leptin withdrawal

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

An inflammatory cascade leading to hyperresistinemia in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Adipose tissue, adipokines, and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Tumor necrosis factor alpha inhibits signaling from the insulin receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Transforming growth factor beta and the liver

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

The utility of radiological imaging in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Nonalcoholic fatty liver disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Liver fibrosis in overweight patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Noninvasive assessment of liver fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Long term prognosis of fatty liver: risk of chronic liver disease and death.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Natural history of NAFLD: remarkably benign in the absence of cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Excess weight risk factor for alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Risk factors of fibrosis in alcohol-induced liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Effect of weight reduction on hepatic abnormalities in overweight patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

The evolution of severe steatosis after bariatric surgery is related to insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0505

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0505

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17515890%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference